En Es
Productos
Covid-19
Compañías
Segunda mano
Noticias
Eventos
Acerca de nosotros:       ¡Únase ahora!
Categorías

Ver productos por categoría

Cuidados intensivos

Medicina de emergencia

Cuidados intensivos

Cuidado respiratorio

Sistemas de Anestesiología

Cuidados domiciliarios

Rehabilitación

Otro

Infraestructura hospitalaria

Equipamiento TI

Sistemas de Transporte

Gestión de residuos

Otro

Imágenes medicas

Tomografía computarizada

Radiografía Digital

Sistemas de gestión de imágenes

Radiología intervencionista

Imágenes por resonancia magnética

Mamografía

PACS / RIS

Tomografía de emisión de positrones

Seguridad de las radiaciones

Radiografía

Tomografía computarizada de emisión de fotón único

Ultrasonido

Otro

Atención al paciente

Cuidado bariátrico

Camas

Equipos de examen

Otro

Cirugía

Endoscopia

Laparoscopia

Cirugía laser

Equipamiento de quirófano

Esterilización

Implantes quirúrgicos

Instrumentos quirúrgicos

Gestión de residuos

Otro

Expo: Laboratorio clínico

Analizadores de Sangre y Gas

Contadores de Células

Centrífugas

Analizador de Química Clínica

Analizadores de Coagulación

Laboratorio General

Analizadores de Hematología

Sistemas de Inmunoensayo

Cristalería de Laboratorio

Lector de Microplacas

Microscopios

Pipetas

Pruebas Rápidas

Kits para Análisis Listos para Usar

Analizador de Orina

Pruebas Punto de Atención

Ver productos por categoría

Cerrar

Billion to One

Billion to One

BillionToOne is a molecular diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's QCT molecular counter platform is the only technology that can count DNA molecules at the single-count level with single base-pair precision.
Productos Resumen
Close

Sobre Billion to One

BillionToOne is a molecular diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's QCT molecular counter platform is the only technology that can count DNA molecules at the single-count level with single base-pair precision.

Actualizado

Non-Invasive Prenatal Test (NIPT)
UNITY Screen

UNITY Screen is the only commercially available non-invasive prenatal test (NIPT) that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw at 10+ weeks into pregnancy. It is able to quantify the tiny DNA changes floating in cell-free DNA using the company’s molecular counting technology. UNITY does not require a paternal blood sample to assess fetal risk, supporting more equitable care and enabling more pregnancies at risk to be affected with recessive conditions to be identified early in pregnancy as compared to traditional carrier screening.
Mas detalles

Tumor Burden Liquid Biopsy Test
Northstar Response (RUO)

The Northstar Response is a liquid biopsy test that provides longitudinal determination of cancer burden via methylation assessment. It determines multi cancer methylation signature (nucleotides are methylated in specific locations in cancers) and enables quantification of changes in tumor burden using the company’s molecular counting technology. The Northstar Response liquid biopsy test is currently available for research use only.
Mas detalles

Tumor Mutation Liquid Biopsy Test
Northstar Select (RUO)

The Northstar Select is a liquid biopsy test that provides a prioritized list of mutations, including deletions, insertions, and point-mutations, present in the tumor. At the same time, it helps rule-in/rule-out relationship of mutations to drugs and provides an accurate read on the covered genes. The Northstar Select liquid biopsy test is currently available for research use only.
Mas detalles

Laboratorio clínico

Non-Invasive Prenatal Test (NIPT)
UNITY Screen

UNITY Screen is the only commercially available non-invasive prenatal test (NIPT) that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw at 10+ weeks into pregnancy. It is able to quantify the tiny DNA changes floating in cell-free DNA using the company’s molecular counting technology. UNITY does not require a paternal blood sample to assess fetal risk, supporting more equitable care and enabling more pregnancies at risk to be affected with recessive conditions to be identified early in pregnancy as compared to traditional carrier screening.
Mas detalles

Tumor Burden Liquid Biopsy Test
Northstar Response (RUO)

The Northstar Response is a liquid biopsy test that provides longitudinal determination of cancer burden via methylation assessment. It determines multi cancer methylation signature (nucleotides are methylated in specific locations in cancers) and enables quantification of changes in tumor burden using the company’s molecular counting technology. The Northstar Response liquid biopsy test is currently available for research use only.
Mas detalles

Tumor Mutation Liquid Biopsy Test
Northstar Select (RUO)

The Northstar Select is a liquid biopsy test that provides a prioritized list of mutations, including deletions, insertions, and point-mutations, present in the tumor. At the same time, it helps rule-in/rule-out relationship of mutations to drugs and provides an accurate read on the covered genes. The Northstar Select liquid biopsy test is currently available for research use only.
Mas detalles
Derecho de autor © 2000-2026 TradeMed.com. Todos los derechos reservados. | Términos y condiciones